Contact
searchSearch
HMP Global
Login
Videos

Consolidation Therapy After Clinical Complete Response in Muscle-Invasive Bladder Cancer

03/15/2026


At Great Debates Solid Tumors in Miami, Florida, Joshua Linscott, MD, PhD, from Moffitt Cancer Center in Tampa, Florida, discusses the role of consolidation therapy in muscle-invasive bladder cancer after a clinical complete response to chemotherapy. 

Dr Linscott reviews the clinical rationale for consolidation approaches and highlights emerging biomarkers including ctDNA and urinary tumor DNA that may help guide treatment decisions and identify patients who could potentially avoid additional therapy.

Source: 

Linscott J. Consolidation after clinical complete response in muscle-invasive bladder cancer: Oncologic necessity vs outdated over-treatment.Presented at Great Debates - Solid Tumors; Miami, Florida. March 14-15, 2026. 


At Great Debates Solid Tumors in Miami, Florida, Joshua Linscott, MD, PhD, from Moffitt Cancer Center in Tampa, Florida, discusses the role of consolidation therapy in muscle-invasive bladder cancer after a clinical complete response to chemotherapy. 

Dr Linscott reviews the clinical rationale for consolidation approaches and highlights emerging biomarkers including ctDNA and urinary tumor DNA that may help guide treatment decisions and identify patients who could potentially avoid additional therapy.

Source: 

Linscott J. Consolidation after clinical complete response in muscle-invasive bladder cancer: Oncologic necessity vs outdated over-treatment.Presented at Great Debates - Solid Tumors; Miami, Florida. March 14-15, 2026. 

Related Content

Arnab Basu, MD
Videos
Emerging Bladder Preservation Strategies for Patients With Muscle-Invasive Bladder Cancer
03/19/2026
Arnab Basu, MD, discusses emerging bladder preservation strategies in muscle-invasive bladder cancer in the setting of novel neoadjuvant therapies.
Arnab Basu, MD, discusses emerging bladder preservation strategies in muscle-invasive bladder cancer in the setting of novel neoadjuvant therapies.
Arnab Basu, MD, discusses...
03/19/2026
Oncology
Guru Sonpavde, MD
Videos
ctDNA Guided Adjuvant Therapy for Patients With Muscle-Invasive Bladder Cancer
03/14/2026
Guru Sonpavde, MD, discusses whether ctDNA-guided adjuvant therapy should be used in patients with high-risk muscle-invasive bladder cancer.
Guru Sonpavde, MD, discusses whether ctDNA-guided adjuvant therapy should be used in patients with high-risk muscle-invasive bladder cancer.
Guru Sonpavde, MD, discusses...
03/14/2026
Oncology
Matthew Galsky, MD, Icahn School of Medicine at Mount Sinai
Videos
Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves Outcomes in Muscle-Invasive Bladder Cancer
03/02/2026
Matthew Galsky, MD
Matthew Galsky, MD, discusses results from the phase 3 KEYNOTE-B15/EV-304 study evaluating perioperative enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer.
Matthew Galsky, MD, discusses results from the phase 3 KEYNOTE-B15/EV-304 study evaluating perioperative enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer.
Matthew Galsky, MD, discusses...
03/02/2026
Oncology
Pooja Ghatalia, MD
Videos
RETAIN-2 Supports Response-Adapted Bladder Preservation in Muscle-invasive Bladder Cancer
02/27/2026
Pooja Ghatalia, MD
Pooja Ghatalia, MD, discusses results from the phase 2 RETAIN-2 trial and integrated ctDNA analysis from RETAIN-1 and RETAIN-2 evaluating response-adapted bladder preservation in muscle-invasive bladder cancer.
Pooja Ghatalia, MD, discusses results from the phase 2 RETAIN-2 trial and integrated ctDNA analysis from RETAIN-1 and RETAIN-2 evaluating response-adapted bladder preservation in muscle-invasive bladder cancer.
Pooja Ghatalia, MD, discusses...
02/27/2026
Oncology

Recent News

FDA Approval
FDA Approves Nivolumab Plus Doxorubicin, Vinblastine, and Dacarbazine for Previously Untreated Patients With Advanced Classical Hodgkin Lymphoma
03/20/2026
Emily Estrada
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG...
03/20/2026
Oncology
News
Botensilimab Plus Balstilimab Demonstrates Promise in Refractory Metastatic Colorectal Cancer
03/18/2026
Emily Estrada
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative...
03/18/2026
Oncology
News
Belzutifan Plus Lenvatinib Improves PFS in Advanced Clear Cell Renal Cell Carcinoma
03/11/2026
Stephanie Holland
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3...
03/11/2026
Oncology
News
Mezigdomide Plus Carfilzomib and Dexamethasone Improves PFS in R/R Multiple Myeloma
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3...
03/11/2026
Oncology
News
FDA Approves Piflufolastat F 18 Injection for the Detection of PSMA-Positivity Among Patients With Prostate Cancer
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute
FDA Alerts
Ipsen Voluntarily Withdraws Tazemetostat Following Updated Safety Findings from the SYMPHONY-1 Trial
03/11/2026
Stephanie Holland
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data...
03/11/2026
Oncology
News
Pimicotinib Maintains Favorable Safety Profile in Tenosynovial Giant Cell Tumor
03/11/2026
Stephanie Holland
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the...
03/11/2026
Oncology
News
Cemiplimab Improves Disease-Free Survival in High-Risk Cutaneous Squamous Cell Carcinoma
03/05/2026
Stephanie Holland
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST...
03/05/2026
Oncology
FDA Approval
FDA Approves Teclistamab Plus Daratumumab Hyaluronidase for Relapsed or Refractory Multiple Myeloma
03/05/2026
Emily Estrada
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase...
03/05/2026
Oncology
News
Tokyo-172 BCG is Noninferior to TICE BCG in High-Risk Non-Muscle Invasive Bladder Cancer
03/04/2026
Emily Estrada
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study...
03/04/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use